Document is current
Any future updates will be listed below
-
Authors
Pasanisi, Justine
Lamy, Constance
Lecompte, Lolita
Vacher, Sophie
Schwartz, Mathias
Hamza, Abderaouf
Caputo, Sandrine M.
Ibadioune, Sabrina
Courtois, Laura
Berger, Frédérique
Cockenpot, Vincent
Baulande, Sylvain
Pierga, Jean-Yves
Callens, Celine
Melaabi, Samia
Colas, Chrystelle
Pasmant, Eric
Kamal, Maud
Dupain, Célia
Servant, Nicolas
Le Tourneau, Christophe
Bièche, Ivan
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-EQPX-03/ANR10-INBS-09-08)
Cancéropôle Ile-de-France
Site de recherche intégré contre le cancer
- License Information
-
More Information
Article History
Received: 3 November 2025
Accepted: 24 January 2026
First Online: 7 February 2026
Competing interests
: Maud Kamal: Roche and AstraZeneca; Christophe Le Tourneau: Roche, Seattle Genetics, Rakuten, Nanobiotix, MSD, BMS, Merck Serono, AstraZeneca, GlaxoSmithKline, Novartis, Celgene, Exscientia, ALX Oncology and Seattle Genetics; Ivan Bièche: AstraZeneca. No other potential conflicts of interest were reported.
